Ju Han
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ju Han has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
Jun Zhang
Department of Neurology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, China; Shandong Artificial Intelligence Institute, Qilu University of Technology (Shandong Academy of Sciences), Jinan, China
19 shared publicationsYun Song
Department of Neurology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, China
18 shared publicationsHao Yin
Department of Neurology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, China
16 shared publicationsLili Sun
Department of Neurology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, China
16 shared publicationsMeimei Zheng
Department of Neurology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, China
16 shared publicationsWei Wang
Department of Neurology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, China
15 shared publications
Latest Publications
- 11 February 2026
- Published by Elsevier in Atherosclerosis
- Vol. 415, 120678
Endovascular treatment for non-acute intracranial vertebrobasilar artery occlusion in Chinese elderly: Efficacy and safety outcomes
- 11 February 2026
- Published by Elsevier in Atherosclerosis
- Vol. 415, 120678
Endovascular treatment for non-acute intracranial vertebrobasilar artery occlusion in Chinese elderly: Efficacy and safety outcomes
- Open Access
- 7 January 2026
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 16, 1686858
Drug-coated balloon versus conventional balloon for stent angioplasty in symptomatic intracranial atherosclerotic stenosis
Background: Due to limited evidence on the optimal strategy for intracranial atherosclerotic stenosis (ICAS), further evidence on the safety and efficacy of drug-coated balloon (DCB) predilation stent angioplasty was aimed to be provided. Methods: Consecutive patients with symptomatic medically refractory ICAS from January 2016 to November 2022 who underwent balloon predilation stent angioplasty were retrospectively analyzed and dichotomized by whether DCB or conventional balloon (CB) was used. The efficacy and safety endpoints were compared by propensity score matching. Results: A total of 95 patients in the DCB group and 100 patients in the CB group were selected. Of these, 134 patients were matched. The in-stent restenosis (ISR) incidence (1.5% vs. 16.4%, p = 0.006) and the median (IQR) stenosis degree at follow-up in the DCB group were significantly lower than those in the CB group [0(0) vs. 0(0), p = 0.031]. The primary safety endpoint within 30 days and secondary safety endpoints from 31 days to 1 year were not statistically different between the two groups. Conclusion: Compared with CB predilation stent angioplasty, DCB predilation stent angioplasty effectively reduced the degree of restenosis and the risk of ISR, but had no advantage in terms of symptomatic restenosis risk currently. However, these findings should be interpreted cautiously because of the aforementioned limitations, and prospective multicenter randomized studies with larger patient number will be required to establish the efficacy and safety of DCB.
- 7 January 2026
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 16, 1686858
Open AccessDrug-coated balloon versus conventional balloon for stent angioplasty in symptomatic intracranial atherosclerotic stenosis
Background: Due to limited evidence on the optimal strategy for intracranial atherosclerotic stenosis (ICAS), further evidence on the safety and efficacy of drug-coated balloon (DCB) predilation stent angioplasty was aimed to be provided. Methods: Consecutive patients with symptomatic medically refractory ICAS from January 2016 to November 2022 who underwent balloon predilation stent angioplasty were retrospectively analyzed and dichotomized by whether DCB or conventional balloon (CB) was used. The efficacy and safety endpoints were compared by propensity score matching. Results: A total of 95 patients in the DCB group and 100 patients in the CB group were selected. Of these, 134 patients were matched. The in-stent restenosis (ISR) incidence (1.5% vs. 16.4%, p = 0.006) and the median (IQR) stenosis degree at follow-up in the DCB group were significantly lower than those in the CB group [0(0) vs. 0(0), p = 0.031]. The primary safety endpoint within 30 days and secondary safety endpoints from 31 days to 1 year were not statistically different between the two groups. Conclusion: Compared with CB predilation stent angioplasty, DCB predilation stent angioplasty effectively reduced the degree of restenosis and the risk of ISR, but had no advantage in terms of symptomatic restenosis risk currently. However, these findings should be interpreted cautiously because of the aforementioned limitations, and prospective multicenter randomized studies with larger patient number will be required to establish the efficacy and safety of DCB.
- Open Access
- 7 October 2025
- Published by Springer Nature in Journal of Inflammation
- Vol. 22 (1) , 1-13
Current perspectives on the pathogenesis of cerebral atherosclerosis
To summarize the current understanding of the pathogenesis of cerebral atherosclerosis to provide a basis for developing effective treatments and exploring future research directions for clinical application. (1) Pathophysiological processes: Endothelial dysfunction and oxidative stress are crucial in the early stage of atherosclerotic plaque formation. Lipid accumulation, especially of low-density lipoprotein, promotes plaque growth and instability. Inflammatory responses exacerbate vascular damage, resulting in plaque rupture and thrombosis. (2) Genetic factors: Genetic studies have identified several loci associated with increased susceptibility to cerebral atherosclerosis, indicating potential therapeutic targets, including APOEε4, RNF213, NTNG1, and CYP2C19. (3) Daily diet also plays a role in the development of the disease. Healthy patterns (Mediterranean, DASH) with good nutrients and less bad fats/sodium can reduce cerebral atherosclerosis risk and improve cerebrovascular health. (1) This review presents recent progress in understanding the mechanisms of intracranial atherosclerosis, covering genetics, inflammation, comorbidities, diet, and exercise aspects. It reveals that managing blood pressure, lipids, glucose, and consistent moderate-intensity physical activity benefits vascular health. Controlling inflammation spread and maintaining cerebral vessel structure are linked to slowing the disease, suggesting therapeutic and genetic targets. (2) Nevertheless, there are gaps. Most mechanisms come from small-scale, single-center clinical studies, mainly focusing on extracranial atherosclerosis and plaque formation. Their reliability needs large-scale, multi-center validation. Besides, basic research is hampered by challenges of intracranial atherosclerosis animal models, like long duration, instability, and tissue-collecting difficulty. (3) Thus, large - scale clinical imaging can better describe intracranial atherosclerosis features. Also, specific animal models should be developed to offer more stable and reliable evidence and guidance for treating this disease.
- 7 October 2025
- Published by Springer Nature in Journal of Inflammation
- Vol. 22 (1) , 1-13
Open AccessCurrent perspectives on the pathogenesis of cerebral atherosclerosis
To summarize the current understanding of the pathogenesis of cerebral atherosclerosis to provide a basis for developing effective treatments and exploring future research directions for clinical application. (1) Pathophysiological processes: Endothelial dysfunction and oxidative stress are crucial in the early stage of atherosclerotic plaque formation. Lipid accumulation, especially of low-density lipoprotein, promotes plaque growth and instability. Inflammatory responses exacerbate vascular damage, resulting in plaque rupture and thrombosis. (2) Genetic factors: Genetic studies have identified several loci associated with increased susceptibility to cerebral atherosclerosis, indicating potential therapeutic targets, including APOEε4, RNF213, NTNG1, and CYP2C19. (3) Daily diet also plays a role in the development of the disease. Healthy patterns (Mediterranean, DASH) with good nutrients and less bad fats/sodium can reduce cerebral atherosclerosis risk and improve cerebrovascular health. (1) This review presents recent progress in understanding the mechanisms of intracranial atherosclerosis, covering genetics, inflammation, comorbidities, diet, and exercise aspects. It reveals that managing blood pressure, lipids, glucose, and consistent moderate-intensity physical activity benefits vascular health. Controlling inflammation spread and maintaining cerebral vessel structure are linked to slowing the disease, suggesting therapeutic and genetic targets. (2) Nevertheless, there are gaps. Most mechanisms come from small-scale, single-center clinical studies, mainly focusing on extracranial atherosclerosis and plaque formation. Their reliability needs large-scale, multi-center validation. Besides, basic research is hampered by challenges of intracranial atherosclerosis animal models, like long duration, instability, and tissue-collecting difficulty. (3) Thus, large - scale clinical imaging can better describe intracranial atherosclerosis features. Also, specific animal models should be developed to offer more stable and reliable evidence and guidance for treating this disease.
- Open Access
- 1 October 2025
- Published by Japan Atherosclerosis Society in Journal of Atherosclerosis and Thrombosis
- Vol. 32 (10) , 1223-1234
Recanalization for Symptomatic Non-acute Intracranial Large Vessel Occlusion: An Observational Study
Aim: This study investigated the efficacy and safety of endovascular revascularization for symptomatic non-acute atherosclerotic intracranial LVO.Methods: For non-acute atherosclerotic intracranial large vessel occlusion (LVO), despite aggressive medical treatment, recurrent ischemic stroke or transient ischemic attack related to the occluded artery still occurs repeatedly. This retrospective cohort study included stroke patients with intracranial LVO who received endovascular treatment (EVT), categorized by successful recanalization and the time interval from symptom onset to revascularization (<30 days vs. ≥ 30 days). The primary efficacy outcome was stroke recurrence or mortality at the 6-month follow-up.Results: Of the 264 patients in the study, 229 (87%) had successful recanalization, while 35 (13%) did not. In addition, 139 patients had recanalization times ≤ 30 days, and 125 had recanalization times >30 days. The successful recanalization group had a significantly lower rate of stroke recurrence or death during follow-up than the unsuccessful group (9.6% vs. 31.4%, adjusted odds ratio [OR]: 4.98, 95% confidence interval [CI]: 1.86 -13.37; P = 0.001). The group with a recanalization time ≤ 30 days also demonstrated a significantly lower rate of stroke recurrence or death during follow-up than the group with a recanalization time >30 days (7.9% vs.17.6%, P = 0.015). In addition, the rate of a favorable prognosis (modified Rankin Scale [mRS] 0-2) during the follow-up period was significantly higher in the successful recanalization group than in the successful recanalization group (71.1% vs. 51.4%, P = 0.021).Conclusion: These findings suggest that successful recanalization may have therapeutic potential for patients with non-acute intracranial large-vessel occlusion, particularly for those with LVO recanalization lasting <30 days, who show more significant benefits than those with longer-lasting recanalization [please check this carefully].
- 1 October 2025
- Published by Japan Atherosclerosis Society in Journal of Atherosclerosis and Thrombosis
- Vol. 32 (10) , 1223-1234
Open AccessRecanalization for Symptomatic Non-acute Intracranial Large Vessel Occlusion: An Observational Study
Aim: This study investigated the efficacy and safety of endovascular revascularization for symptomatic non-acute atherosclerotic intracranial LVO.Methods: For non-acute atherosclerotic intracranial large vessel occlusion (LVO), despite aggressive medical treatment, recurrent ischemic stroke or transient ischemic attack related to the occluded artery still occurs repeatedly. This retrospective cohort study included stroke patients with intracranial LVO who received endovascular treatment (EVT), categorized by successful recanalization and the time interval from symptom onset to revascularization (<30 days vs. ≥ 30 days). The primary efficacy outcome was stroke recurrence or mortality at the 6-month follow-up.Results: Of the 264 patients in the study, 229 (87%) had successful recanalization, while 35 (13%) did not. In addition, 139 patients had recanalization times ≤ 30 days, and 125 had recanalization times >30 days. The successful recanalization group had a significantly lower rate of stroke recurrence or death during follow-up than the unsuccessful group (9.6% vs. 31.4%, adjusted odds ratio [OR]: 4.98, 95% confidence interval [CI]: 1.86 -13.37; P = 0.001). The group with a recanalization time ≤ 30 days also demonstrated a significantly lower rate of stroke recurrence or death during follow-up than the group with a recanalization time >30 days (7.9% vs.17.6%, P = 0.015). In addition, the rate of a favorable prognosis (modified Rankin Scale [mRS] 0-2) during the follow-up period was significantly higher in the successful recanalization group than in the successful recanalization group (71.1% vs. 51.4%, P = 0.021).Conclusion: These findings suggest that successful recanalization may have therapeutic potential for patients with non-acute intracranial large-vessel occlusion, particularly for those with LVO recanalization lasting <30 days, who show more significant benefits than those with longer-lasting recanalization [please check this carefully].
- Open Access
- 15 August 2025
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 16, 1570728
Drug-coated balloon angioplasty versus conventional angioplasty for symptomatic non-acute intracranial artery occlusion
Background and objective: Non-acute intracranial artery occlusion (ICAO) is an important cause of recurrent ischemic stroke despite aggressive medical treatment. Conventional angioplasty has high incidences of perioperative complications and restenosis in treating these patients. Drug-coated balloon (DCB) treatment has shown superiority in preventing restenosis. This study aimed to compare the DCB angioplasty with conventional angioplasty in symptomatic ICAO patients.Methods: From January 2016 to March 2024, consecutive patients with symptomatic non-acute ICAO treated with endovascular therapy were enrolled and dichotomized by whether DCB was used. Propensity score matching analysis was used to compare the perioperative complications, clinical and imaging follow-up results of the two groups.Results: 158 eligible patients were included in this study. There were 104 cases in the DCB group and 54 cases in the non-DCB group. A total of 92 matched patients were selected for propensity score matching analysis. At 6 months follow-up, the median stenosis degree (19.3% [0% ~ 34.3%] vs. 43.6% [22.8% ~ 80.2%], p = 0.009) and total restenosis incidence (10.9% [5/46] vs. 39.1% [18/46], p = 0.004) were significantly lower in the DCB group. There were no statistically significant differences in the incidences of perioperative complications (8.7% vs. 17.4%, p = 0.388), symptomatic restenosis (2.2% vs. 8.7%, p = 0.375) and recurrent ischemic events (4.3% vs. 10.9%, p = 0.453) between the two groups.Conclusion: In patients with symptomatic non-acute ICAO, compared with conventional angioplasty, DCB angioplasty can effectively reduce the restenosis degree and restenosis risk.
- 15 August 2025
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 16, 1570728
Open AccessDrug-coated balloon angioplasty versus conventional angioplasty for symptomatic non-acute intracranial artery occlusion
Background and objective: Non-acute intracranial artery occlusion (ICAO) is an important cause of recurrent ischemic stroke despite aggressive medical treatment. Conventional angioplasty has high incidences of perioperative complications and restenosis in treating these patients. Drug-coated balloon (DCB) treatment has shown superiority in preventing restenosis. This study aimed to compare the DCB angioplasty with conventional angioplasty in symptomatic ICAO patients.Methods: From January 2016 to March 2024, consecutive patients with symptomatic non-acute ICAO treated with endovascular therapy were enrolled and dichotomized by whether DCB was used. Propensity score matching analysis was used to compare the perioperative complications, clinical and imaging follow-up results of the two groups.Results: 158 eligible patients were included in this study. There were 104 cases in the DCB group and 54 cases in the non-DCB group. A total of 92 matched patients were selected for propensity score matching analysis. At 6 months follow-up, the median stenosis degree (19.3% [0% ~ 34.3%] vs. 43.6% [22.8% ~ 80.2%], p = 0.009) and total restenosis incidence (10.9% [5/46] vs. 39.1% [18/46], p = 0.004) were significantly lower in the DCB group. There were no statistically significant differences in the incidences of perioperative complications (8.7% vs. 17.4%, p = 0.388), symptomatic restenosis (2.2% vs. 8.7%, p = 0.375) and recurrent ischemic events (4.3% vs. 10.9%, p = 0.453) between the two groups.Conclusion: In patients with symptomatic non-acute ICAO, compared with conventional angioplasty, DCB angioplasty can effectively reduce the restenosis degree and restenosis risk.
- Open Access
- 24 May 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-8
Risk factors of restenosis after paclitaxel-coated balloon treatment in symptomatic intracranial atherosclerotic disease
Paclitaxel-coated balloon (PCB) treatment has shown promise for intracranial atherosclerotic disease (ICAD). However, studies on restenosis and its associated factors after PCB use are lacking. This study aimed to elucidate risk factors of restenosis after PCB treatment for ICAD. We retrospectively enrolled consecutive patients who had been successfully treated with PCBs for symptomatic ICAD between January 2016 and December 2022. Eligible patients were classified into “no-restenosis” and “restenosis” groups by follow-up DSA. Demographic, clinical, laboratory test, and angiographic data were analyzed. Multivariate logistic regression analysis was used to explore the risk factors of restenosis after PCB treatment. A total of 261 eligible patients were enrolled in this study. There was no death and there were 6.51% (17/261) patients had ipsilateral stroke within 30 days. During 6 months clinical follow up, there was no death and there were 3.07% (8/261) patients had ipsilateral stroke after 30 days, and 13.41% (35/261) patients were identified with restenosis. The restenosis group had significantly higher follow-up hs-CRP (P = 0.040), higher stenosis degree (P = 0.011), higher total occlusion rate (P = 0.009), longer lesion length (P < 0.001), higher residual stenosis after intervention (P < 0.001) and lower stenting rate (P = 0.017).Multivariate logistic regression analysis showed that baseline neutrophil count (OR 1.356, 95% CI 1.015–1.812; P = 0.039), lesion length (OR 1.113, 95% CI 1.032–1.199; P = 0.005) and residual stenosis after intervention (OR 1.066, 95% CI 1.036–1.097; P < 0.001) were risk factors of restenosis.
- 24 May 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-8
Open AccessRisk factors of restenosis after paclitaxel-coated balloon treatment in symptomatic intracranial atherosclerotic disease
Paclitaxel-coated balloon (PCB) treatment has shown promise for intracranial atherosclerotic disease (ICAD). However, studies on restenosis and its associated factors after PCB use are lacking. This study aimed to elucidate risk factors of restenosis after PCB treatment for ICAD. We retrospectively enrolled consecutive patients who had been successfully treated with PCBs for symptomatic ICAD between January 2016 and December 2022. Eligible patients were classified into “no-restenosis” and “restenosis” groups by follow-up DSA. Demographic, clinical, laboratory test, and angiographic data were analyzed. Multivariate logistic regression analysis was used to explore the risk factors of restenosis after PCB treatment. A total of 261 eligible patients were enrolled in this study. There was no death and there were 6.51% (17/261) patients had ipsilateral stroke within 30 days. During 6 months clinical follow up, there was no death and there were 3.07% (8/261) patients had ipsilateral stroke after 30 days, and 13.41% (35/261) patients were identified with restenosis. The restenosis group had significantly higher follow-up hs-CRP (P = 0.040), higher stenosis degree (P = 0.011), higher total occlusion rate (P = 0.009), longer lesion length (P < 0.001), higher residual stenosis after intervention (P < 0.001) and lower stenting rate (P = 0.017).Multivariate logistic regression analysis showed that baseline neutrophil count (OR 1.356, 95% CI 1.015–1.812; P = 0.039), lesion length (OR 1.113, 95% CI 1.032–1.199; P = 0.005) and residual stenosis after intervention (OR 1.066, 95% CI 1.036–1.097; P < 0.001) were risk factors of restenosis.
- Open Access
- 4 April 2025
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 12, 1493342
Case Report: Endovascular therapy for an iatrogenic vertebrojugular arteriovenous fistula and pseudoaneurysm induced by multiple vascular procedures
Vertebrojugular arteriovenous fistula (VJAVF) and vertebral artery pseudoaneurysm (VAPA) are usually caused by iatrogenic and penetrating traumas. The concurrence of these two entities originating from different ostia of the vertebral artery (VA) is extremely rare. The history of repeated open-heart surgery and the application of central venous catheterization during anesthesia increased the risk of VA injuries and its complications of the VJAVF and VAPA. The patient, who complained of dizziness, was initially diagnosed with bradycardia and aortic paravalvular leak. However, the symptoms persisted even after permanent pacemaker implantation and transcatheter closure of the aortic paravalvular leak. Ultrasonography, CT angiography, and intraoperative right subclavian arteriography showed a VJAVF originating from the right VA and draining into the right internal jugular vein. A VAPA originated from another ostium of the right VA without a drainage vessel. Using the endovascular technique, a 4 mm stent graft was deployed in a 3.6 mm VA to cover both the VJAVF and the VAPA ostia. The symptoms of dizziness disappeared. The VJAVF and VAPA were completely sealed without recurrence at the 6-month follow-up.
- 4 April 2025
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 12, 1493342
Open AccessCase Report: Endovascular therapy for an iatrogenic vertebrojugular arteriovenous fistula and pseudoaneurysm induced by multiple vascular procedures
Vertebrojugular arteriovenous fistula (VJAVF) and vertebral artery pseudoaneurysm (VAPA) are usually caused by iatrogenic and penetrating traumas. The concurrence of these two entities originating from different ostia of the vertebral artery (VA) is extremely rare. The history of repeated open-heart surgery and the application of central venous catheterization during anesthesia increased the risk of VA injuries and its complications of the VJAVF and VAPA. The patient, who complained of dizziness, was initially diagnosed with bradycardia and aortic paravalvular leak. However, the symptoms persisted even after permanent pacemaker implantation and transcatheter closure of the aortic paravalvular leak. Ultrasonography, CT angiography, and intraoperative right subclavian arteriography showed a VJAVF originating from the right VA and draining into the right internal jugular vein. A VAPA originated from another ostium of the right VA without a drainage vessel. Using the endovascular technique, a 4 mm stent graft was deployed in a 3.6 mm VA to cover both the VJAVF and the VAPA ostia. The symptoms of dizziness disappeared. The VJAVF and VAPA were completely sealed without recurrence at the 6-month follow-up.
- 18 December 2024
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 17 (e2) , e405-e411
Vessel wall MRI evaluation for the safety of endovascular recanalization of non-acute intracranial anterior circulation artery occlusions
Background Vessel wall MRI (VWMRI) can reveal the morphological features of intracranial artery occlusion (ICAO). This study aimed to investigate the imaging features of ICAO on VWMRI and explore their correlation with perioperative complications of endovascular recanalization for non-acute ICAO. Methods The study retrospectively included consecutive patients with recurrent ischemic stroke due to non-acute ICAO in the anterior circulation who underwent preoperative VWMRI evaluation and endovascular recanalization. Perioperative complications included ischemic and hemorrhagic strokes within 30 days after operation. Imaging features of the occluded segments were evaluated on precontrast and post-contrast VWMRI, including occlusion length and site, vessel wall area, signal intensity, angle, and shape of the occluded segment. The associations between the clinical and imaging features and perioperative complications were examined. Results One hundred and four patients were included in the analysis, of whom 22.1% (23/104) had perioperative complications. After adjusting for multiple confounding variables, four imaging risk factors were identified that were independently associated with perioperative complications, that is, the angle between the occluded and pre-occluded artery segments (OR 11.60, 95% CI 2.73 to 49.29), occluded artery segment shape (OR 13.07, 95% CI 2.82 to 60.67), vessel wall collapse before occlusion (OR 2.91, 95% CI 0.96 to 8.77), and post-contrast mean signal intensity ratio at the ¼ point of the occluded artery segment Conclusions VWMRI may be helpful to select patients with non-acute ICAO who are suitable for endovascular recanalization.
- 18 December 2024
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 17 (e2) , e405-e411
Vessel wall MRI evaluation for the safety of endovascular recanalization of non-acute intracranial anterior circulation artery occlusions
Background Vessel wall MRI (VWMRI) can reveal the morphological features of intracranial artery occlusion (ICAO). This study aimed to investigate the imaging features of ICAO on VWMRI and explore their correlation with perioperative complications of endovascular recanalization for non-acute ICAO. Methods The study retrospectively included consecutive patients with recurrent ischemic stroke due to non-acute ICAO in the anterior circulation who underwent preoperative VWMRI evaluation and endovascular recanalization. Perioperative complications included ischemic and hemorrhagic strokes within 30 days after operation. Imaging features of the occluded segments were evaluated on precontrast and post-contrast VWMRI, including occlusion length and site, vessel wall area, signal intensity, angle, and shape of the occluded segment. The associations between the clinical and imaging features and perioperative complications were examined. Results One hundred and four patients were included in the analysis, of whom 22.1% (23/104) had perioperative complications. After adjusting for multiple confounding variables, four imaging risk factors were identified that were independently associated with perioperative complications, that is, the angle between the occluded and pre-occluded artery segments (OR 11.60, 95% CI 2.73 to 49.29), occluded artery segment shape (OR 13.07, 95% CI 2.82 to 60.67), vessel wall collapse before occlusion (OR 2.91, 95% CI 0.96 to 8.77), and post-contrast mean signal intensity ratio at the ¼ point of the occluded artery segment Conclusions VWMRI may be helpful to select patients with non-acute ICAO who are suitable for endovascular recanalization.
- Open Access
- 18 October 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (21) , e036474
Enhancing Blood–Brain Barrier Integrity in Patients With Acute Ischemic Stroke Via Normobaric Hyperoxia
BACKGROUND: Recent advancements in animal studies have demonstrated the potential of normobaric hyperoxia (NBO) as a promising intervention for preserving the integrity of the blood–brain barrier (BBB). However, there is still limited understanding of the effects of NBO on BBB function in patients with clinical stroke. Therefore, the objective of this study was to investigate the efficacy of NBO therapy in attenuating BBB damage and reducing brain injury in individuals undergoing endovascular treatment (EVT) for acute stroke. METHODS AND RESULTS: This study enrolled patients from the OPENS‐1 (Normobaric Hyperoxia Combined With Reperfusion for Acute Ischemic Stroke) study, with 43 patients receiving NBO combined with EVT and 43 patients receiving EVT alone. The main outcome measures included serum levels of occludin, MMP‐9 (matrix metalloproteinase‐9), NSE (neuron‐specific enolase), and S100b at 24 hours and 7 days, as well as the intracranial extravasation rate at 24 hours. Serum markers were assessed using ELISA, and intracranial contrast extravasation was visualized using dual‐energy computed tomography scan. We analyzed a total of 86 patients and found that the 24‐hour serum markers levels of BBB damage and brain injury were significantly lower in the group receiving NBO therapy combined with EVT compared with the group receiving EVT alone. Similarly, at 7 days, the levels of occludin, MMP‐9, and NSE were lower in the NBO+EVT group. We also found that the 24‐hour serum levels of occludin and MMP‐9 were correlated with intracranial contrast extravasation. Additionally, the incidence of intracranial contrast extravasation was lower in the NBO+EVT group compared with the EVT group (35.9% versus 60.5%, P =0.031). CONCLUSIONS: This study offers valuable insights into the positive impact of NBO on maintaining BBB integrity and reducing brain injury in patients with acute stroke undergoing EVT.
- 18 October 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (21) , e036474
Open AccessEnhancing Blood–Brain Barrier Integrity in Patients With Acute Ischemic Stroke Via Normobaric Hyperoxia
BACKGROUND: Recent advancements in animal studies have demonstrated the potential of normobaric hyperoxia (NBO) as a promising intervention for preserving the integrity of the blood–brain barrier (BBB). However, there is still limited understanding of the effects of NBO on BBB function in patients with clinical stroke. Therefore, the objective of this study was to investigate the efficacy of NBO therapy in attenuating BBB damage and reducing brain injury in individuals undergoing endovascular treatment (EVT) for acute stroke. METHODS AND RESULTS: This study enrolled patients from the OPENS‐1 (Normobaric Hyperoxia Combined With Reperfusion for Acute Ischemic Stroke) study, with 43 patients receiving NBO combined with EVT and 43 patients receiving EVT alone. The main outcome measures included serum levels of occludin, MMP‐9 (matrix metalloproteinase‐9), NSE (neuron‐specific enolase), and S100b at 24 hours and 7 days, as well as the intracranial extravasation rate at 24 hours. Serum markers were assessed using ELISA, and intracranial contrast extravasation was visualized using dual‐energy computed tomography scan. We analyzed a total of 86 patients and found that the 24‐hour serum markers levels of BBB damage and brain injury were significantly lower in the group receiving NBO therapy combined with EVT compared with the group receiving EVT alone. Similarly, at 7 days, the levels of occludin, MMP‐9, and NSE were lower in the NBO+EVT group. We also found that the 24‐hour serum levels of occludin and MMP‐9 were correlated with intracranial contrast extravasation. Additionally, the incidence of intracranial contrast extravasation was lower in the NBO+EVT group compared with the EVT group (35.9% versus 60.5%, P =0.031). CONCLUSIONS: This study offers valuable insights into the positive impact of NBO on maintaining BBB integrity and reducing brain injury in patients with acute stroke undergoing EVT.
- 9 April 2024
- Published by Wolters Kluwer Health in Neurology
- Vol. 102 (7) , e209217
Efficacy and Safety of Tirofiban Before Stenting for Symptomatic Intracranial Atherosclerotic Stenosis
Background and ObjectivesAcute stent thrombosis (AST) is not uncommon and even catastrophic during intracranial stenting angioplasty in patients with symptomatic high-grade intracranial atherosclerotic stenosis (ICAS). The purpose of this study was to ...
- 9 April 2024
- Published by Wolters Kluwer Health in Neurology
- Vol. 102 (7) , e209217
Efficacy and Safety of Tirofiban Before Stenting for Symptomatic Intracranial Atherosclerotic Stenosis
Background and ObjectivesAcute stent thrombosis (AST) is not uncommon and even catastrophic during intracranial stenting angioplasty in patients with symptomatic high-grade intracranial atherosclerotic stenosis (ICAS). The purpose of this study was to ...